One of us recently received exciting molecular testing results: a patient’s newly diagnosed metastatic colorectal cancer expressed microsatellite instability, a predictive biomarker for immunotherapy. The patient fell into the minority of patients with metastatic colorectal cancer for whom precision oncology truly alters the natural history of disease, potentially prolonging survival by years. Providing biomarker-driven immunotherapy certainly exemplified the tenets of precision oncology.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zafar SY, Sanoff HK. Changing the Course of Cancer Care With Greater Precision. JAMA Oncol. 2020;6(5):634–636. doi:10.1001/jamaoncol.2019.6843
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.